Transplantation of the kidney by Starzl, TE et al.
It has now been more than 30 years since the first 
attempt was made at human renal homotransplantation. 
The early efforts to apply this form of therapy to the treat- 
ment of terminal renal disease were doomed to failure since 
they preceded an appreciation of the problems to be 
encountered. Knowledge of homograft rejection was 
scanty and the therapy necessary to prevent this process 
was not understood at all. Since that time, a rational 
explanation of rejection has been provided by the studies 
of Medawar and those of other investigators. The evidence 
is overwhelming that rejection is due to immunologic 
repudiation of the alien tissue by the host. The intensity 
of this reaction is related to the degree of genetic dissimi- 
larity between the donor and the recipient. Its prevention 
depends to a greater or lesser extent upon crippling of the 
host's capacity for immunologic response to unfamiliar 
antigens. 
The initial attempts at potentiating homograft function 
by alteration of the host were made with total body 
irradiation. Such therapy proved to be of value for the 
prevention of rejection, but the requisite dosage was so 
high that most of the recipient patients died from bone 
marrow depression and sepsis. Despite the exorbitant 
risk imposed, three patients are still living from this 
pioneer era, the longest follow-ups being on two young 
men treated almost six years ago by Murray and Merrill 
and by Hamburger with homografts from their fraternal 
twins. Today, American centres do not generally use 
total body irradiation although it remains an important 
element in the overall therapy employed by Hamburger 
and some of the other European authorities; with in- 
creased experience, Hamburger's later results with irradia- 
tion are not dissimilar to those obtained by other groups 
with drug therapy. 
In spite of the occasional early encouraging experience, 
the prospect of achieving significant clinical benefit from 
renal homotransplantation in more than the isolated 
case seemed remote indeed except when an identical twin 
donor was available (isograft) until the discovery by 
Schwartz and Dameshek of the immunosuppressive pro- 
perties of dmercaptopurine in 1959 and the subsequent 
testing of this drug and its analogue, azathioprine, by 
Calne and Zukoski. It seemed that prevention of homo- 
graft rejection could be accomplished with greater regu- 
larity and with less risk to the recipient than had been 
possible with total body irradiation; long-term homo- 
graft viability was achieved in animals without the 
appearance of concomitant host leukopenia or agranulo- 
cytosis. During the ensuing several years, clinical efforts 
at homotransplantation of the kidney have proceeded 
with increasing regularity. By September 15, 1964, 
almost 500 such potentially therapeutic operations were 
known to have been performed throughout the world 
by virtue of their entry into the National Academy of 
Science Registry. 
Candidates for Homotransplantation 
The requirements for candidacy are simple. The 
patient should have irreversible renal disease from which 
life expectancy is limited to a few weeks or months. 
There should be a normal lower urinary tract. Other 
serious disease processes must be ruled out. Transplanta- 
tion is ordinarily a procedure which should be reserved for 
the relatively young. In patients older than 45 years, the 
failure rate has been high in most centres, the patient 
often dying of complications originating in other organ 
systems. 
Very frequently an interim period of intensive resuscita- 
tive therapy is mandatory before a decision for or against 
transplantation can be made. On many occasions a 
prospective recipient has entered the hospital in acute 
heart failure with severe hypertension, anasarca, or with a 
variety of neurologic complications including profound 
coma. In most instances these findings can be rapidly 
reversed by the institution of emergency dialysis. If this 
proves to be impossible, the likelihood of subsequent 
successful transplantation is almost nil. A sipficant 
improvement is often necessary prior to operation for the 
patient to have a reasonable chance of tolerating the trauma 
of surgery and the duress of the post-operative period. 
Donor Selection 
Renal tissue is available from three general sources. 
First, there is now ample evidence that cadaveric kidneys 
can often provide good function. Recently, considerable 
success with such organs has been achieved by KolfT, 
Hume, Mowbray, and Hamburger despite the fact that 
there is a high incidence of immediate functional failure 
of such kidneys, due primarily to ischamic injury. A 
variable degree of damage is inevitable in the terminal 
premortem state of the donor, to which is added an addi- 
tional devascularized period during removal and transfer. 
The harmful effects of the latter "dead time" can be con- 
siderably minimized by quickly cooling the kidney after 
its excision (Fig. 16). 
The improved results obtained by the groups cited above 
have largely been due to the very carefully controlled 
circumstances of the undertaking. Most of the recipient 
patients had been previously maintained in good clinical 
condition on a chronic dialysis programme. When the 
cadaveric transplant was carried out it merely represented 
an incident in a programme of continuing therapy with the 
artificial kidney. Thus, patients who did not have im- 
mediate homograft function could be maintained by an 
extension of their pre-existing care until recovery from 
an acute tubular necrosis in the homograft. Ultimately 
good function has been observed under such circumstances 
despite initial post-transplant anuria of as long as a month. 
Volunteer living donors provide a second source of 
renal homografts. Here, the entire procedure for both 
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donor and recipient can be planned in advance and exe- 
cuted with precision. The transplanted kidneys almost 
invariably work well immediately after operation since 
the donors are in good health, the ischremic intervals are 
short, and, m addition, the homografts can be further 
protected, just as with cadaveric kidneys, by perfusion 
with a cold electrolyte solution immediately after removal. 
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Fro. 16. Method of wld perfusion of renal homograft. 
Various other solutions have ben! evaluated including 
low molecular weight Dextran, either aloneor in wmbina- 
tion with blood. plasma, or saline. All work relatively 
well, the principal beneficial effect being the rapidly in- 
duced hypothennia. 
Finally, it may ultimately become possible to use renal 
heterografts obtained from subhuman primate donors. 
Efforts have been made to transplant chimpanzee, baboon, 
and Rhesus kidneys to man, with surprisingly good and 
unexpectedly persistent function. The Rhesus heterograft 
transplanted by Reemtsma excreted urine in its human 
environment for almost a week, and the baboon kidneys 
used at the University of Colorado functioned for as 
long as 2 months. One of Reemtsma's patients, who 
received a pair of chimpanzee kidneys, survived with 
good to fair renal function for 9 months. Despite these 
encouraging notes all 20 patients treated with various 
heterografts are now dead, and it seems unlikely that 
consistent success can be obtained with the presently 
available immunosuppressive regimens. 
The source of the transplanted tissue has to date been 
the most inlportant biologic determinant of success or 
failure. In controlled animal experiments, it has been 
established that the vigour of rejection is directly related to 
the degree of genetic dissimilarity between the donor and 
recipient. It is not surprising, therefore, that the best 
results have been when blood relatives have provided the 
homografts, as will be described in a subsequent section. 
Non-related donors have been less satisfactory, and the 
poorest results have been with heterografts. In all classes, 
however, the outcome is still unpredictable in the individual 
case. Violent and uncontrollable rejection episodes have 
occurred with familial homografts. Conversely, non- 
related homografts or even chimpanzee heterografts have 
on occasion incited little clinically detectable host reaction. 
These findings suggest that a wide spectrum of donor- 
recipient histocompatibility exists with employment of 
any of these donor pools. Until now, quantitation of 
histocompatibility factors in the human has not been 
possible in a precise way, in spite of the efforts of a number 
of investigators. When such techniques become available, 
it will be possible to match the prospective recipient with 
an appropriate donor, thereby eliminating much of the 
guesswork in donor selection. 
Blood Group Considerations 
When possible, donors and recipients are selected of the 
same ABO blood groups. This is not essential, however. 
Various mismatch combinations appear not to carry 
an increased risk providing the transplant is not placed 
into a recipient whose plasma contains preformed hamag- 
glutinins directed against red cell antigens which are 
present in the renal cells of patients who belong to Blood 
Groups A, B, and AB. For example, a person of 0 type 
can provide a kidney for a recipient of any blood group 
since the renal tissue of such a donor does not contain 
A or B isoantigens which could bind with hamagglutinins 
present in recipients of A, B, or 0 group. The 0 patient 
is thus the universal donor. Because the kidney of an 
individual with AB blood contains both A and B isoanti- 
gens, he could safely donate only to an AB recipient. 
Conversely, he could accept a kidney from any donor 
(universal recipient) since his plasma does not contain 
anti-A or anti-B hamareglutinins. The rules of tissue 
transfer across blood group barriers are, therefore, the 
same as those which apply to the use of non-matched 
blood in blood banks (Table 2). It is noteworthy that 
TABLE 2 
DIRECTION OP ACCEPTABLE MISMATCHED TISSUE TRANSFER* 
0 to non-0 Safe 
Rh- to Rh+ Safe 
Rh+ to Rh- Relatively safe 
A to non-A Dangerous 
B to non-B Dangerous 
AB to non-AB ' Dangerous 
0 is universal donor. AB fr universal recipient. 
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long survival has been obtained despite violation of 
this scheme. One patient at the University of Colorado 
has normal renal function 2J years after B to A horno- 
transplantation. Nevertheless, a number of immediate 
failures have occur-red after similar mismatches. 
Both the donor and recipient operations involve the use 
of standard surgical techniques. Donor nephrectomy is 
more easily accomplished than nephrectomy in renal 
disease but it must be done with greater care in order to 
provide undamaged vessels and ureter for anastomosis. 
It is highly desirable, when living donors are used, to 
perform pre-operative renal arteriography to determine if 
there are anomalies of blood supply. 
The recipient operation is also quite simple. Ordinarily, 
the kidney is placed in the iliac fossa contralateral to 
its donor location, reversing the anteroposterior relation- 
ships of the hilar structures. In this way the ureter and 
pelvis are anterior, the renal artery in an intermediate 
position, and the renal vein posterior. The host hypogastric 
artery and external iliac vein are connected to the renal 
vessels; urinary drainage is provided by performing 
ureteroneocystostomy or ureteroureterostomy. Under 
various circumstances modifications of this technique are 
necessary either because of the small size of the recipient, 
or because of disease in the pelvic vessels. It is often 
desirable and sometimes obligatory to remove the recipient 
patient's own diseased kidneys either at the time of trans- 
plantation or at a separate operation. This can easily be 
done through a short upper midline incision. 
If a technically successful homotransplantation is 
carried out there is massive early post-operative diuresis. 
In unusual cases this has exceeded 100 ml per hour with 
the resultant need for meticulous management of fluid 
and electrolyte replacement. With this restoration of 
renal function there is a dramatic improvement in the 
patient's general condition, which persists until the time 
of homograft rejection. 
The Events of Rejection - 
The most useful agent for the prevention of rejection 
has been azathioprine. Important additive benefits have 
been ascribed to prednisone, actinomycin-C and local 
homograft irradiation. Although these agents attenuate 
the vigour of rejection, they frequently do not altogether 
prevent its clinical manifestation. A quite typical example 
of homograft rejection in a patient receiving immuno- 
suppression is illustrated in Figure 17. There was excellent 
renal function for more than two weeks after receipt of a 
homograft from his younger brother. His convalescence 
was then interrupted by an abrupt drop in creatinine 
clearance, relative oliguria, a secondary rise in blood- 
urea, fever, and proteinuria. The addition of prednisone 
and actinomycin C to pre-existing therapy with azathio- 
prine was followed by a reversal of all of these adverse 
findings. 
The demonstration that most rejection episodes can be 
reversed is one of the fundamental disclosures which has 
made clinical homotransplantation a practical possi- 
bility. Moreover, it is now clear that the drastic immuno- 
suppressive measures frequently required for reversal of 
rejection are not needed permanently. Thus, in the patient 
described (Fig. 17), the large doses of prednisone which 
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FIG. 17. Classical rejection crisis in a patient being treated 
with immunosuppressive drugs. Deterioration of renal 
function began 17 days after transplantation. All stigmata 
of rejection are present except for acute hypertension and 
weight gain, which were successfully prevented by medi- 
cal treatment. The transplantation was on April 17, 
1963. Renal function was completely normal in August. 
1965. Biopsy of the homograft after two yean was 
normal. Acti-C-actinomycin C; LN-left ncphrectomy 
at the time of transplantation; RN-right nephrectomy. 
Imuran is synonymous with azathioprine. 
were temporarily necessary could be quickly reduced, 
and in this case they were discontinued altogether within 
5 months. Such observations suggest that some alteration 
occurs in the relationship between the homograft and the 
host with the passage of time which diminishes the diffi- 
culty of controlling rejection. Whether this change occurs 
in the homograft, as suggested by W o o d d ,  or in the 
host, or both, is not known. 
The combination of a.zathioprine and prednisone pro- 
vides the cornerstone of immunosuppressive therapy in 
most centres but Calne and Hume have also demonstrated 
the value of actinomycin-C and local homograft irradia- 
tion. Figure 18 illustrates the course of a patient who 
received all four forms of therapy in December of 1963. 
In this case the graft repudiation was unusually violent, 
leading to temporary anuria. The rejection episode was 
reversed and the patient is still alive with good function 
after more than one and a half years. 
Thymectomy and splenectomy. Although the thera- 
peutic methods alluded to above are of more or less un- 
questioned value, two other biological manipulations have 
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been carried out in many cases although they are of un- 
known worth. In several patients thymectomy was per- 
formed prior to transplantation, primarily because of the 
evidence in rodent experiments by Miller that the thymus 
WBC 
Ra. 18. Use of intravenous actinomycin-C and local irradia- 
tion to the homograft during a severe rejection crisis. 
Note the development of  anuria by the fourth post-opera- 
tive day. Homotransplantation was done December 4. 
1963. The patient is still alive with good renal function 
in August. 1965. 
gland is important in the adult in re-establishing reactivity 
to foreign antigens after a period of immunological de- 
pression. The first four patients to receive this procedure 
in Colorado have had extraordinarily benign late courses. 
All have had steroid therapy discontinued for at  least 
1i years and in none has there been evidence of late 
deterioration of homograft function. Since other factors 
such as chance histocompatibility could account for these 
superior results, the contribution of thymectomy is un- 
known. Many more recipient patients have had splenec- 
tomy in an attempt to reduce the host immunological 
reactivity. Much more research will be necessary to define 
whether or not either splenectomy or thymectomy play 
any significant role in potentiation of homograft survival 
in the human. 
Toxicity of Immunosuppressive Agents 
Essential though they are for maintenance of homo- 
graft function, the agents used to protect the homograft 
do so by rendering the patient more susceptible to a 
variety of inimical antigens. It is not surprising, therefore, 
that most of the failures after homotransplantation are due 
to complications of the agents used. A typical lethal 
change of events is shown in Figure 19. The young man 
concerned received a kidney from his brother. After 10 
days of good homograft function a severe rejection crisis 
supervened, with anuria. The rejection was reversed 
but after renal function had returned, the patient became 
leukopenic and died of a fungus and bacterial blood stream 
infection. The margin between therapy and toxicity was 
nonexistent in this case. 
In all centres, bone marrow depression has been the 
outstanding toxic feature encountered in the use of azathio- 
prine. More subtle undesirable effects have been observed 
at a later time. Many patients with homotransplantation 
have developed jaundice late in their course (Fig. 20). 
Since azathioprine is a known hepatotoxic agent, this may 
be nothing more than a direct pharmacologic injury to the 
liver. Alternatively, it may be viral hepatitis in patients 
whose capacity to resist infection has been generally 
weakened. 
Prednisone therapy contributes, of course, to the in- 
creased susceptibility to infection both early and late. 
In addition, the facial and other changes are an annoyance 
to most patients whose late renal function is dependent 
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Ro. 19. Typical unsuccessfully treated case, The donor 
and recipient were brothers, both of A blood type. A 
violent rejection crisis followed good early function, 
and anuria developed which lasted two weeks. Although 
the rejection war reversed and a secondary diuresis began. 
the patient died from drug toxicity, leukopenia, and 
septicornia. Anti-C-Each arrow is 200 p g  intravenous 
actinomycin C. 
upon continuing steroid therapy. Pathological fractures 
have been described in such cases as well as the develop 
ment of lens cataracts; these complications also are prob- 
ably due to the steroids. 
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relative certainty that homotransplantation will have arr 
increasing role in the general medical armamentarium of 
the future. Recent clinical results have exceeded any 
hopes of even a few years ago. Of the first 64 patients 
treated at the University of Colorado Medical Center 
with kidneys from volunteer living donors, 37 homo- 
graft recipients lived for at  least 1 year after opera.tion 
(Fig. 21) and 36 are still alive from 16 to 32 months (mean 
22 months). Within this time limit, the results approach 
acceptability if homografts from genetically related donors 
were used; two-thirds of all those patients who received 
kidneys from blood relatives are still living. With 
unrelated donors the results are poor since only one-third 
lived for as long as 1 year (Fig. 21). In our experience the 
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Fro. 20. Drastic reduction of immunosuppression in a 
patient who became jaundiced after transplantation. 
Note the development of hyperbilirubinirmia while the 
patient was receiving large quantities of azatbioprine, and 
its remission as the dose was reduced. His weight has 
steadily increased as both steroids and azathioprine have 
been withdrawn. Detailed function studies after 21 
months were normal despite a few abnormalities in the 
renal biopsy performed at this time. The homograft was 
provided by the patient's brother. The recipient was A 
blood type; the donor was 0. Late thymectomy was 
performed because of the necessity for attenuation of 
immunosuppression; the value of this adjuvant pro- 
cedure is unproven. 
Late Rejection 
As mentioned above, the necessity for intensive im- 
munosuppressive therapy tends to decrease late after 
operation, and a number of patients have now been 
living for years with no clinical evidence of immunological 
activity directed against the homograft. Nevertheless, a 
significant number of long-term survivors havehad mani- 
festations of late rejection, sometimes in a form which 
resembles that seen early after operation. These late 
"crises" have proved to be partially reversible with the 
resum~tion of large steroid doses. In such uatients, the 
homobaft functiG can be maintained, but ihe need for 
continuous high dose steroid therapy constitutes a threat 
to a long life expectancy. A more subtle form of late 
rejection without functional manifestations may be 
going on in the "chronic" homografts. Kidneys biopsied 
or recovered at autopsy 1 to 2 years after homotrans- 
plantation frequently contain focal aggregates of mono- 
nuclear cells, a variety of vascular lesions in both the 
large and small vessels, lesions of the glomerular basement 
membrane and patchy interstitial fibrosis. The fate of 
these well-functioning, but morphologically damaged, 
homografts can be determined only by continued observa- 
tion. 
Results and Future Prospects 
Imperfect though the currently employed therapeutic 
methods are, greatly improved early survival after renal 
homotransplantation has been reported from several 
centres and it has already become possible to state with 
Fla. 21. Results after 16 months or longer in 64 consecutive 
patients treated at the University of Colorado Medical 
Center with renal homografts obtained from living 
donors. Identical twin cases are not included. Only 1 
death has occurred after 1 year. Note that more than 
two-thirds of patients who received kidneys from blood 
relatives are alive from 16 to 32 months after transplanta- 
tion. Only a third of those whose donors were unrelated 
lived as long as a year. 
best survival within the related group was with parent- 
to-offspring transplants, 70 per cent of the recipients 
still being alive (Fig. 22). In the world experience, sibling 
to sibling transfers have had the highest success rate. 
These results as well as similar pooled statistics from the 
National Science Foundation Transplant Registry indicate 
that many uraemic patients, perhaps even the majority, 
can be materially benefited by renal homotransplantation 
with relatively complete social and vocational rehabilita- 
tion over considerable periods of time. Nevertheless, 
-- 
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Whether this is true or not can be determined only by 
actual observation. In the meanwhile there is legitimate 
reason for avoiding overoptimism. Not all patients 
who have reached a late stage of convalescence are well. 
As mentioned above, there is evidence of continued host- 
against-graft immunological activity in many of these long 
surviving patients. It is possible that most of the apparently 
well patients are living by virtue of renal homografts 
which are losing a small fraction of functioning parenchyma 
each day. For the moment, therefore, it would seem most 
reasonable to regard renal homotransplantation as an 
effective, but incompletely characterized, form of palliative 
therapy. Ultimately it may be proven that it is a curative 
Flo. 22. Breakdown of results at the University of Colorado procedure, but that time has not yet arrived. 
Medical Center in patients who received kidneys from 
blood relatives other than indentical twins from 16 to 32 
months ago. The best results were with parental dona- FURTHER READING 
tions; in the world experience, however, sibling to sibling 
transplants have fared somewhat bettar. Calne, R. Y. (1963), Renal Transplantation. Baltimore: Williams & 
Wilkins. 
workers in the field who have repeatedly warned that this 
treatment is experimental are not yet willing to abandon 
this position. The most important reason for a conserva- 
tive attitude is that the ultimate life expectancy of the 
present crop of late survivors is still unknown. Barnes 
has attempted to answer this question in a statistical 
analysis of the death rate of those patients already treated 
and has predicted that further losses from the group of 
patients still living will occur at  an extremely gradual rate. 
Hamburger,J., Crosnier, J. and Dormont, J. (1965). "Experience with 
45 Renal Homotransplantations in Man." Lancet, 1,985. 
Hume. D. M., Magee, J. H., Prout, G. R., Jr., Kauffrnan, H. M., Jr., 
Cleveland, R. H., Bower, J. D. and Lee, H. M. (1964). "Studies of 
Renal Homotransplantation in Man," Ann. New York Acad. Sci, 
120,578. 
Murray. J. E., Gleason,E. and Bartholornay, A. (1965), "Third Report 
of the Human Kidney Transplant Registry ." Transplantation, 3,294. 
Russell, P .  S. and Monaco, A. P. (1965), The Biology of TissYc 
Transplantation. Boston : Little Brown. 
Starjrl, T. E. (1964), Experience in Renal Transplantation. Philadelphia: 
Saunders. 
